Diverse definitions of the early course of schizophrenia - a 

targeted literature review by Newton, Richard et al.
REVIEW ARTICLE OPEN
Diverse deﬁnitions of the early course of schizophrenia—a
targeted literature review
Richard Newton1,7, Alice Rouleau2, Anna-Greta Nylander3, Jean-Yves Loze4, Henrike K. Resemann5, Sara Steeves5 and
Benedicto Crespo-Facorro6
Schizophrenia is a debilitating psychiatric disorder and patients experience signiﬁcant comorbidity, especially cognitive and
psychosocial deﬁcits, already at the onset of disease. Previous research suggests that treatment during the earlier stages of disease
reduces disease burden, and that a longer time of untreated psychosis has a negative impact on treatment outcomes. A targeted
literature review was conducted to gain insight into the deﬁnitions currently used to describe patients with a recent diagnosis of
schizophrenia in the early course of disease (‘early’ schizophrenia). A total of 483 relevant English-language publications of clinical
guidelines and studies were identiﬁed for inclusion after searches of MEDLINE, MEDLINE In-Process, relevant clinical trial databases
and Google for records published between January 2005 and October 2015. The extracted data revealed a wide variety of
terminology and deﬁnitions used to describe patients with ‘early’ or ‘recent-onset’ schizophrenia, with no apparent consensus. The
most commonly used criteria to deﬁne patients with early schizophrenia included experience of their ﬁrst episode of schizophrenia
or disease duration of less than 1, 2 or 5 years. These varied deﬁnitions likely result in substantial disparities of patient populations
between studies and variable population heterogeneity. Better agreement on the deﬁnition of early schizophrenia could aid
interpretation and comparison of studies in this patient population and consensus on deﬁnitions should allow for better
identiﬁcation and management of schizophrenia patients in the early course of their disease.
npj Schizophrenia  (2018) 4:21 ; doi:10.1038/s41537-018-0063-7
INTRODUCTION
Schizophrenia can be a debilitating psychiatric disorder, with the
majority of patients experiencing signiﬁcant comorbidity through-
out the course of their illness. Studies have reported cognitive and
psychosocial deﬁcits already at the onset of disease,1 and a
negative impact of longer time of untreated psychosis on
treatment outcomes.2,3 Despite continued development of
pharmacological, psychosocial and other treatment modalities
over the last 5 decades, many patient outcomes often remain
poorly managed, especially with regards to negative symptoms
and cognitive impairment.4
Current evidence suggests that individuals with schizophrenia
are not only at considerable psychosocial risks, but also at risk of
biological harm that may be associated with relapse.5 Research
has further proposed that treating patients during the earlier
stages of schizophrenia reduces the likelihood or frequency of
relapse, reduces disease burden and provides patients with more
favourable outcomes, including in the long term.3,6–8
The lack of standardised deﬁnitions of early schizophrenia
allows for considerable variation of patient groups between
studies and limits analysis of comparative effectiveness of the
interventions used. There is therefore an increasing interest for
consensus regarding deﬁnitions of early stage disease. The aim of
this targeted literature review was to map deﬁnitions currently
used to describe patients with a recent diagnosis of schizophrenia
who are early in the disease course (‘early course’ schizophrenia),
as reported in clinical guidelines and as used in study inclusion
criteria.
RESULTS
Literature search and study characteristics
1845 articles from MEDLINE/MEDLINE in-process and 656 records
from clinical trial registries were identiﬁed and reviewed for
relevance. From these records, 466 primary studies used some
form of early schizophrenia terminology. A total of 17 relevant
treatment guidelines were identiﬁed and included in the review.
Across all studies included in the review, a large proportion of
studies were conducted in Europe (n= 177). Further, 66 studies
from North America were identiﬁed, 19 studies from Australia and
204 studies from elsewhere in the world (Table 1). Most included
studies were cross-sectional observational studies (n= 279), with
further featured study designs including longitudinal observa-
tional studies (n= 92), randomised controlled trials (n= 50) and
other interventional studies (n= 45).
Terminology used in treatment guidelines
Most of the 17 identiﬁed treatment guidelines divided the patient
population into those with a ﬁrst episode of psychosis and those
with recurrent episodes, and did not provide additional deﬁnitions
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of early schizophrenia.9–25 Three guidelines also included alter-
native terminology for patients with early schizophrenia as distinct
from ﬁrst-episode schizophrenia.26–28 In 2011, the American
Psychiatric Association deﬁned 'early course' as the period after
recovery from a ﬁrst episode of schizophrenia and extending up to
the subsequent 5 years.26 Llorca et al. (2013) considered 'early
course' to apply to patients who had been newly diagnosed with
schizophrenia and who had had no previous antipsychotic
treatment.27 The Schizophrenia Patient Outcomes Research Team
(2010) used the term “recent onset schizophrenia”, but no
associated deﬁnition was speciﬁed.28
Deﬁnitions used in primary studies
Across the 466 primary studies using some form of early
schizophrenia deﬁnition, three main deﬁnition types were
identiﬁed (Fig. 1): episode-based deﬁnitions (n= 401), duration-
based deﬁnitions (n= 147) and symptom severity-based deﬁni-
tions (n= 23). Episode-based deﬁnitions included those selecting
patients on the basis of the number of psychotic episodes they
have experienced. Duration-based deﬁnitions were deﬁnitions
based on time since the start of illness, such as time since
symptom onset, diagnosis or start of treatment. Symptom
severity-based deﬁnitions included deﬁnitions based on current
severity of symptoms and/or referring to the staging of
schizophrenia as detailed in treatment guidelines.
There were 370 (79%) studies which used a single deﬁnition
type, while the remaining 96 (21%) studies used overlapping
deﬁnitions (e.g. ﬁrst-episode and a duration-based deﬁnition).
Stratifying these groups by study location revealed broadly similar
patterns, with slightly higher proportions of European studies
using single rather than overlapping deﬁnition types (Fig. 2). No
substantial differences between the proportion of single and
overlapping deﬁnitions were seen when stratifying by study
design (Fig. 2).
Episode-based deﬁnitions. Of the 401 studies using episode-
based deﬁnitions, 98% (n= 392) used ‘ﬁrst-episode’ to deﬁne the
enroled schizophrenia patient population. Nine studies did include
multi-episode patients within a deﬁnition of early schizophrenia,
but deﬁnitions were variable. Of these studies, three deﬁned early
schizophrenia in patients who had experienced <3 episodes.29–31
A further three studies selected early schizophrenia in patients
who had experienced ≥1 episode with duration of illness ≤5
years,32–34 while an additional three studies deﬁned early
schizophrenia in patients who had experienced ≥2 episodes of
relapse, again with an upper disease duration limit of 5 years,35–37
one of which required patients to have been hospitalised for those
relapses.37
Duration-based deﬁnitions. Across primary studies using
duration-based deﬁnitions to select patients, nearly half did not
specify the disease onset deﬁnition used (71/147; 48%).32,36,38–106
The remaining 52% (n= 76) of studies used a variety of deﬁnitions
for disease onset, including ﬁve studies that used multiple onset
deﬁnitions: 29 studies referred to time since symptom onset;107–
135 14 studies referred to time since ﬁrst episode or acute
phase;33,34,136–147 17 studies referred to time since ﬁrst presenta-
tion to mental health services, hospitalisation or admission;138,148–
163 17 studies referred to time since schizophrenia diagno-
sis;37,108,137,164–177 and 5 studies referred to time since treatment
had ﬁrst been initiated.35,108,109,149,178
In total, 142 of these studies selected patients with disease
duration of less than a particular period of time to deﬁne early
schizophrenia.32–36,38–58,60–75,77–139,141–175,177,178 Durations ranged
from <1 month to <10 years, while 1, 2 or 5 years were the
most common duration cut-offs used with duration-based criteria









Europe 177 37,180 2005–2015
Australia 19 1484 2005–2015
Othera 204 30,372 2005–2015
a Other regions included Asia (n= 175), Middle East (n= 10), Central/South
America (n= 8), Africa (n= 3) or encompassed multiple regions (n= 8)
Fig. 1 Summary of deﬁnitions used in primary studies (N= 466) identiﬁed in the literature review
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(Fig. 3). 91% (129/142) of studies did not provide a rationale for
the duration cut-offs used. Of the remaining 9% (13/142) that did
specify a rationale for their duration-based deﬁnitions, six
established their deﬁnitions on prior experience and evi-
dence,34,90,93,150,152,164 while seven studies provided study-
speciﬁc rationale (Table 2).32,42,45,52,63,154,169
Finally, seven studies selected patients with disease duration
between two periods of time to deﬁne early schizophrenia,
ranging from 6 months to 7 years in length, starting from 1 month
since diagnosis to as late as 24 months thereafter.35,37,59,74,76,140,176
Two of these studies had also used ‘less than’ disease duration
deﬁnitions with cut-offs of <1 year and <2 years, respectively, to
deﬁne a separate subgroup of schizophrenia patients with earlier
disease.35,74
Symptom severity-based deﬁnitions. The review identiﬁed 22
relevant studies that incorporated symptom severity-based
deﬁnitions (e.g. requiring patients to be in an acute phase of
Fig. 2 Proportion of studies (N= 466) using single vs overlapping early schizophrenia deﬁnitions; stratiﬁed by a study location and b design
Fig. 3 Distribution of cut-offs used with duration-based criteria, stratiﬁed by disease onset deﬁnition (n). Footnote: studies with multiple
deﬁnitions were repeated under each category (n= 5)
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the disease or in a stable phase or remission).30,32,36,37,40,48,67,76–
78,100,137,172,173,178–185 All of these studies used the symptom
severity criteria in combination with a duration or episode-based
deﬁnition. It should be noted that in many of the ﬁrst-episode
studies it was often implied that these patients were in the acute
phase of an episode, however as symptom severity was not a
formal patient selection criterion these studies were therefore not
included under this deﬁnition type. One additional study employ-
ing the 5-stage model proposed by McGorry et al. to describe the
onset of psychiatric disorders for the purposes of selecting
patients for the study was identiﬁed. This study included patients
who fulﬁlled the criteria for stage 2 (ﬁrst episode of psychosis).42
Early schizophrenia terminology
The most commonly used terminology for early schizophrenia
included ‘ﬁrst-episode’, ‘recent-onset’, ‘early-phase’, ‘early course’,
‘early’ and ‘early stage’ schizophrenia. Terminology varied some-
what between studies using the duration, episode and/or severity
deﬁnitions. In particular, the terms ‘ﬁrst-episode’ and ‘recent-
onset’ were more frequently used in studies that included disease
duration or severity deﬁnitions, whereas studies with multi-
episode deﬁnitions tended to use terms such as ‘early phase’ or
‘early course’. However, there was no clear association of particular
terms with speciﬁc deﬁnitions.
DISCUSSION
From the results of this literature review it is clear that a wide
variety of deﬁnitions are being used to describe patients with early
schizophrenia, likely based on the different study types repre-
sented in the review and their objectives for patient inclusion. The
majority of guidelines used the terminology ‘ﬁrst-episode
psychosis’ when discussing patients early in the course of the
disease, while in primary studies, the most commonly used
criterion to deﬁne early schizophrenia, was for patients to be in
their ﬁrst episode of schizophrenia, followed by application of
disease duration limits, frequently disease duration less than 1, 2
or 5 years. Only a small number of studies used multi-episode or
symptom severity/staging criteria to select patients with early
schizophrenia. The majority of studies did not use a combination
of deﬁnitions, with many studies simply identifying patients being
in their ﬁrst episode of schizophrenia.
The onset of psychosis has been found to be difﬁcult to
determine, as onset may be rapid or more subtle, and may be
preceded by months to years of prodromal disease.186 Further,
although in the majority of cases time of symptom onset is
obtained from parents or close relatives, in some cases it may rely
on patients’ recollection only, causing additional variability. There
were wide variations in deﬁnitions used to mark the onset of
schizophrenia in studies identiﬁed in this review as using duration-
based deﬁnitions, with a large proportion of studies not specifying
when illness or disease was considered to start. Of the studies that
did provide a deﬁnition, the most common was to refer to time
since symptom onset, however no studies provided clear
information on how the ﬁrst occurrence of symptoms was
detected. As a result, there may be variation in how the deﬁnition
was applied between patients, and also between studies. The next
most common deﬁnitions of onset were ﬁrst presentation to
mental health services, hospitalisation or admission, and ﬁrst
diagnosis. While these may be more objectively measured than
symptom onset, by this stage patients have already developed
psychotic symptoms, and therefore it could be argued that the
onset of schizophrenia occurred some time before this point.
A number of review articles have discussed the validity of using
episode-based deﬁnitions in schizophrenia, particularly ‘ﬁrst-
episode’ deﬁnitions, highlighting difﬁculties including the lack of
a consensus deﬁnition of ‘ﬁrst-episode schizophrenia’,187,188 and
the fact that ﬁrst-episode samples may still show great hetero-
geneity due to potential uncertainty of a schizophrenia diagnosis
at the ﬁrst episode and variation in illness duration.8,188,189 Use of
multi-episode deﬁnitions is further complicated by the need to
deﬁne when one episode has ended and the next has started. The
lack of a standardised deﬁnition of ‘relapse’ has been highlighted
in a systematic review of observational studies,190 and few studies
using multi-episode deﬁnitions identiﬁed in the present review
speciﬁed a deﬁnition for relapse. The majority of studies that did
deﬁne relapse in this review used hospitalisation as a proxy for
identifying it, which may be problematic as patients could be
hospitalised for reasons other than a worsening of symptoms and
conversely, patients may suffer a worsening of symptoms but not
be hospitalised. This is particularly true in countries where crisis
management teams have been implemented in the community
setting. Other studies used a symptom severity scale as part of the
deﬁnition for relapse, but there was variation in the scales used as
well as the cut-off scores used with those scales. Only one of the
studies using multi-episode deﬁnitions identiﬁed in this review
deﬁned how subsequent episodes were measured, deﬁning these
as relapses requiring psychiatric hospitalisation.37
With regards to deﬁnitions using symptom severity, an article
by Francey et al. (2010) suggested that use of symptom severity
alone may not be sufﬁcient in deﬁning ﬁrst-episode schizophrenia,
particularly when determining whether antipsychotic medications
should be used.189 Further, duration-based deﬁnitions are ﬂawed
by limitations such as difﬁculties in reliably measuring symptom
duration, especially retrospective estimation of the duration of
untreated psychosis,191 as well as heterogeneity between patients,
particularly when a long disease duration is allowed.
Although no clear differences in the types of deﬁnition used were
seen when stratifying studies by study design, a somewhat higher
Table 2. Rationale provided in primary studies for the selection of patients with disease duration under a particular threshold
Rationale based on prior experience and evidence Rationale linked to study methodology
Prior evidence for the time at which schizophrenia reaches a plateau
during the ﬁrst 5 years92
Duration period reduced to minimise confounding due to variation in disease
duration and time on antipsychotic therapy42,45,52,63,154
The majority of the deterioration in psychosocial functioning occurs
within the ﬁrst 3 years93
Duration period extended to increase the number of eligible participants169
Most functional disability occurs within the ﬁrst 5 years of the
disease164
Duration period chosen to maintain consistency with another trial32
Minimum duration of follow-up for ﬁrst-episode studies should be 2
years150
Patients with adolescent onset of schizophrenia and duration less
than 3 years are believed to be in a ‘critical period’152
Progression of the disease might occur predominantly in the ﬁrst 5
years34
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proportion of cross-sectional studies used overlapping deﬁnitions,
whereas other study designs tended to use single deﬁnitions. This
may indicate that cross-sectional studies, many of which were
imaging studies, tended to require a more homogeneous patient
population, whereas for other studies broader deﬁnitions may have
been more appropriate in order to achieve a larger sample size.
In addition to the lack of consensus in deﬁnitions identiﬁed in
this review, terminology used to refer to ‘early schizophrenia’ is
equally heterogeneous. The term ‘early schizophrenia’ itself is
problematic since it may be used both to refer to patients early in
the course of the disease and to patients who have disease onset
at an early age. As a result deﬁnitions such as ‘recent onset’, ‘early
phase’, ‘early course’ and ‘early stage’, were more commonly used
in the literature. As identiﬁed from the review of treatment
guidelines, the term ‘ﬁrst-episode psychosis’ is often used in place
of ‘ﬁrst-episode schizophrenia’. This is in part because at the time
of presenting with a ﬁrst psychotic episode it can be challenging
to establish a diagnosis of schizophrenia as opposed to other
psychiatric diagnoses or other underlying causes.16,19,26 An added
factor relates to the stigma attached to the term ‘schizophrenia’
which may inﬂuence the timing of applying a schizophrenia
‘label’.192,193 Consequently, the use of ‘ﬁrst-episode schizophrenia’
as a term may be more applicable in settings where the deﬁnition
can be applied retrospectively, for example when reviewing the
history of a patient with a conﬁrmed diagnosis of schizophrenia
but no longer in their ﬁrst episode of psychosis.187
From this literature review, there does not appear to be a single
‘best’ deﬁnition of early schizophrenia. Taking the most commonly
used deﬁnitions in this review, the most ‘standard’ deﬁnition is for
patients to be in their ﬁrst episode of schizophrenia, identiﬁed due
to a ﬁrst contact with health services or hospitalisation. For further
reﬁnement, the most common additional criterion used was to
add a disease duration limit of 1, 2 or 5 years from illness onset.
Establishing a consensus deﬁnition of early schizophrenia is
important for several reasons. First, when applied in clinical
practice it can aid prediction of the outcome of different treatment
approaches. For example, it is well established that patients treated
earlier have a better prognosis, but that those earlier in the disease
course can also be more sensitive to treatment side-effects as they
typically have limited prior exposure to antipsychotic agents.19,23 In
this setting the priority should be on establishing a deﬁnition that
is both straightforward to apply and clinically meaningful. In the
context of clinical studies, establishing a consensus deﬁnition
depends somewhat on the study design and objectives. For ease
of comparing results across studies, the emphasis should be on
deﬁnitions that can be applied consistently to minimise hetero-
geneity in the included populations. Thus, we propose that the
onset of early schizophrenia should be set as the point at which
patients ﬁrst develop symptoms severe enough to be considered a
psychotic episode. Regarding the end of early schizophrenia, we
suggest that disease duration of <5 years encompasses previous
deﬁnitions of the critical period for early intervention.194 Within this
broad deﬁnition, it may be possible to identify further subgroups,
taking into account early symptom severity, age of onset and time
to treatment, which have all been found to be prognostic factors
for schizophrenia outcome.195–197 Further investigation of the
impact of these factors through trajectory modelling could help
reﬁne the deﬁnition of early schizophrenia, while a consensus
panel on this topic is required to drive forward consistency in the
way in which early schizophrenia is deﬁned.
Limitations of the review
Limitations of this literature review include single-reviewer
screening and extraction of articles, restriction of searches to
articles published from 2005 onwards and including only articles
written in the English language, while no geographical restrictions
were applied. The search strategy did not include terms for ‘ﬁrst-
episode psychosis’, which may have resulted in some studies
including schizophrenia subgroups within this broader population
being missed. Further, the results of this review are limited by use
of search terms related to ‘early’, rather than searching for all
studies conducted in schizophrenia. While we attempted to
mitigate this by running iterative searches to include additional
terminology identiﬁed through the review, there is the potential
for over- or under-representation of the terms identiﬁed in the
results depending on whether they were used as search terms
themselves. Additionally, the lack of clarity provided in some
publications regarding diagnoses may mean that some studies
with mixed schizophrenia disorder populations were inadvertently
included in the review. For example, studies using the term ‘DSM-
IV for schizophrenia’ despite later referring to a mixture of
schizophrenia, schizoaffective disorder and schizophreniform
patients were excluded, whereas those simply stating ‘DSM-IV
for schizophrenia’ were included.
The focus on deﬁnitions used for participants with diagnosed
schizophrenia in itself means that ﬁndings from this review cannot
be extrapolated to broader populations diagnosed with schizo-
phrenia spectrum disorders. Given the difﬁculty in establishing a
diagnosis at the early stages of schizophrenia, there may be value
in a broader review of the literature in this expanded population.
Nevertheless, since there are differences in the interventions that
are licensed for patients diagnosed with schizophrenia versus
other schizophrenia spectrum disorders, a review of deﬁnitions to
guide therapy in this speciﬁc population is still relevant.
Finally, determination of the frequency of deﬁnitions used was
limited by weighting each included study equally, irrespective of
population number. A series of small studies using the same
deﬁnition may thus have had a higher weighting than a single
larger study.
CONCLUSIONS
A wide variety of deﬁnitions have been used to identify patients
with early schizophrenia, with no apparent consensus. First-
episode schizophrenia is the most frequently reported terminol-
ogy in studies of patients with early schizophrenia, in line with the
clinical guidelines, but even this common terminology is
accompanied by a variety of deﬁnitions, including disease
duration or symptom severity, and neither the terminology nor
the deﬁnitions used are without limitations. When not referring
speciﬁcally to ﬁrst-episode patients, ‘recent-onset’ was the next
most frequently used term, while the duration-based deﬁnitions
most frequently used duration less than 1, 2 or 5 years. Better
agreement on the deﬁnition of early schizophrenia could aid
interpretation and comparison of studies in this patient popula-
tion and consensus on deﬁnitions should allow for better
identiﬁcation and management of schizophrenia patients in the
early course of their disease.
METHODS
Search strategy and selection of studies
For this targeted literature review, searches for published studies,
clinical trial entries and guidelines were conducted between
14.08.2015 and 21.10.2015 using MEDLINE and MEDLINE In-
Process (via PubMed), the Australian New Zealand Clinical Trials
Registry, ClinicalTrials.gov, the EU Clinical Trials Register, the
International Standard Randomised Controlled Trial Number
database, and Google (Data Supplement Table 1–7). Searches for
published studies and clinical trial records were conducted
iteratively, adding in any new terminology for ‘early schizophrenia’
from identiﬁed studies as new search terms, until no further new
terminology was identiﬁed. The searches for relevant guidelines
were updated in May 2016.
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Studies were eligible for inclusion (Data Supplement Table 8) if
they were written in the English language and conducted in
humans, included a distinct population of patients with early
schizophrenia or discussed deﬁnitions of early schizophrenia, and
were published from January 1st 2005. Case studies were
excluded, but there was no other restriction on study design. No
limits were applied regarding interventions, comparators or
outcomes. Articles were reviewed against the eligibility criteria
by a single reviewer. Where the applicability of the eligibility
criteria was unclear, the article was assessed by a second reviewer.
Data extraction and analysis
Information extracted from relevant studies relating to the search
objectives was input into pre-speciﬁed Excel workbooks. Data
extraction was performed by a single individual for each included
study and any uncertainties were reviewed by a second individual.
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